text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 231277-92-2 | Product Number: L0360

Lapatinib


Purity: >98.0%(T)(HPLC)
Synonyms:
  • N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[(2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]quinazolin-4-amine
  • N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
Product Documents:
250MG
₹4,800.00
2   5  
1G
₹5,200.00
Contact Us ≥40 

*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.


Product Number L0360
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__2__9H__2__6ClFN__4O__4S = 581.06 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive,Heat Sensitive
Packaging and Container 250MG-Glass Bottle with Plastic Insert (View image)
CAS RN 231277-92-2
Reaxys Registry Number 10502247
PubChem Substance ID 468592164
MDL Number

MFCD09264194

Specifications
Appearance White to Light yellow powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Volumetric Analysis) min. 98.0 %
Melting point 145.0 to 149.0 °C
NMR confirm to structure
Properties (reference)
Melting Point 147 °C
Maximum Absorption Wavelength 367(MeOH) nm
GHS
Hazard Statements H362 : May cause harm to breast-fed children.
H413 : May cause long lasting harmful effects to aquatic life.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P263 : Avoid contact during pregnancy/ while nursing.
P273 : Avoid release to the environment.
P260 : Do not breathe dusts or mists.
P270 : Do not eat, drink or smoke when using this product.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
Related Laws:
RTECS# VA0952500
Transport Information:
Application
Lapatinib: A Dual Kinase Inhibitor of EGFR and HER2

Lapatinib (GW572016) is a 4-anilinoquinazoline dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. Advanced breast cancer or metastatic breast cancer often overexpress HER2 which is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Lapatinib plus capecitabine [C2878] (a prodrug of 5-FU [F0151]) has shown potent activity in solid tumors, with the most notable in advanced or metastatic breast cancer. (The product is for research purpose only.)

References


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.

TCI
Please enter the required fields (*)
Please enter valid mobile number
New User? *
Add me to your mailing list *

Thank you for signing up!


New subscribers will get FREE TCI Gifts!
We will notify you of further updates on our New products, Offers, Schemes, Discounts, etc.


OK